UNITED THERAPEUTICS CORPORATION
About UNITED THERAPEUTICS CORPORATION
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung transplantation and pulmonary arterial hypertension. It is a public benefit corporation traded on Nasdaq as UTHR and was founded in 1996 by Martine Rothblatt. The company has six FDA-approved therapies for PAH, PH-ILD, and neuroblastoma.
- 🔗 United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization | Nasdaq
- 🔗 United Therapeutics Corporation - UTHR Stock Price Quote & News - M1
- 🔗 United Therapeutics Corporation - 2026 Company Profile & Competitors - Tracxn
- 🔗 United Therapeutics - Wikipedia
- 🔗 United Therapeutics Investor Relations
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Public benefit corporation with Nasdaq listing UTHR.
- Authorized $2 billion share repurchase program through October 2027.
- Six FDA-approved therapies for PAH, PH-ILD and neuroblastoma.
- Founded in 1996 by Martine Rothblatt to address pulmonary arterial hypertension.
- Co-headquartered in Silver Spring, MD and Research Triangle Park, NC.
Ask StreetZero about UNITED THERAPEUTICS CORPORATION
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account